LCM
MACK

Landscape Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Landscape Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,629
Closed -$163K – 1000
2015
Q4 		$163K Buy
+2,629
New +$185K 0.02% 896
2014
Q4 		– Sell
-5,627
Closed -$389K – 642
2014
Q3 		$389K Hold
5,627
– – 0.27% 104
2014
Q2 		$323K Buy
+5,627
New +$286K 0.22% 119

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Landscape Capital Management's MACK Position: Q1 2016 in Review

Landscape Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2016, closing a stake of 2,629 shares — an estimated $163K sold.

Landscape Capital Management first reported a position in MACK in Q2 2014 and held it in 3 quarters. The position peaked at $389K in Q3 2014. 139 funds tracked by Wall St. Rank hold MACK as of Q1 2016.

  • Landscape Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • Landscape Capital Management sold 2,629 Merrimack Pharmaceuticals, Inc. shares in Q1 2016, an estimated $163K.
  • Landscape Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 3 quarters.
  • Landscape Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $389K in Q3 2014.
  • 139 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2016.

Based on Landscape Capital Management's 13F filing for Q1 2016, filed 11 May 2016.